Techcyte Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
121
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$15M
- Investors
-
6
Techcyte General Information
Description
Developer of a first cloud-based digital pathology platform designed to support both anatomic and clinical pathology. The company's platform consists of workflow and AI (Artificial Intelligence) to help labs with the efficiency and accuracy of their diagnostic testing, its technology uses deep learning image analysis and is HIPAA compliant, CE marked, enabling support tests across histology, hematology, cytology, bacteriology, and parasitology, providing human, veterinary, and environmental clinics and labs with AI-powered digital diagnostics tools.
Contact Information
Website
www.techcyte.comCorporate Office
- 1106 North 1200 West
- Orem, UT 84057
- United States
Corporate Office
- 1106 North 1200 West
- Orem, UT 84057
- United States
Techcyte Timeline
Techcyte Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 30-Apr-2026 | $15M | Completed | Generating Revenue | ||
| 9. Later Stage VC (Series F) | 01-Oct-2024 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series E) | 18-Aug-2021 | Completed | Generating Revenue | |||
| 7. Debt - PPP | 15-Apr-2020 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series D) | 01-Feb-2019 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 01-Jul-2017 | Completed | Startup | |||
| 4. Early Stage VC (Series B) | 01-Feb-2016 | Completed | Startup | |||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. Early Stage VC (Series A) | 01-Nov-2013 | $113K | $113K | Completed | Startup | |
| 1. University Spin-Out | 01-Jul-2013 | Completed | Startup |
Techcyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series F | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 3,760,304 | 10% | $0.25 | $0.25 | 1x | $0.25 | 8.9% | |
| Series A | 3,775,405 | 10% | $3 | $3 | 1x | $3 | 8.93% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Techcyte Comparisons
Industry
Financing
Details
Techcyte Competitors (12)
One of Techcyte’s 12 competitors is Proscia, a Formerly VC-backed company based in Philadelphia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Proscia | Formerly VC-backed | Philadelphia, PA | ||||
| Gestalt (Decision/Risk Analysis) | Venture Capital-Backed | Spokane, WA | ||||
| Lumea (Decision/Risk Analysis) | Corporation | Lehi, UT | ||||
| Datexim | Venture Capital-Backed | Caen, France | ||||
| PathPresenter | Venture Capital-Backed | Montville, NJ |
Techcyte Patents
Techcyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12586198-B2 | Image analysis for identifying objects and classifying background exclusions | Active | 18-Feb-2022 | ||
| US-20230281819-A1 | Image analysis for identifying objects and classifying background exclusions | Active | 18-Feb-2022 | ||
| US-20260311477-A1 | Neural network training protocol for automated image analysis for classifying foreground and background regions | Pending | 18-Feb-2022 | ||
| EP-4370933-A2 | Image analysis for classifying hemagglutination and quantifying presence of antibodies | Inactive | 15-Jul-2021 | ||
| EP-4370933-A4 | Image analysis for classifying hemagglutination and quantifying presence of antibodies | Inactive | 15-Jul-2021 | G01N33/5304 |
Techcyte Signals
Techcyte Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mayo Clinic | Corporation | Minority | ||
| Van Tuyl Companies | Family Office | Minority | ||
| ARUP Laboratories | Corporation | Minority | ||
| Zoetis | Corporation | Minority | ||
| Atomic (Private Equity) | Venture Capital | Minority |
Techcyte FAQs
-
When was Techcyte founded?
Techcyte was founded in 2013.
-
Where is Techcyte headquartered?
Techcyte is headquartered in Orem, UT.
-
What is the size of Techcyte?
Techcyte has 121 total employees.
-
What industry is Techcyte in?
Techcyte’s primary industry is Decision/Risk Analysis.
-
Is Techcyte a private or public company?
Techcyte is a Private company.
-
What is Techcyte’s current revenue?
The current revenue for Techcyte is .
-
How much funding has Techcyte raised over time?
Techcyte has raised $51.4M.
-
Who are Techcyte’s investors?
Mayo Clinic, Van Tuyl Companies, ARUP Laboratories, Zoetis, and Atomic (Private Equity) are 5 of 6 investors who have invested in Techcyte.
-
Who are Techcyte’s competitors?
Proscia, Gestalt (Decision/Risk Analysis), Lumea (Decision/Risk Analysis), Datexim, and PathPresenter are some of the 12 competitors of Techcyte.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process